C4 Therapeutics, Inc. (CCCC) shares rallied 13.7% in the last trading session to close at $7.38. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 56.8% gain over the past four weeks.The sudden soaring of the stock price can be attributed to the positive investor mindest regarding the progress of C4's clinical pipeline. The company is evaluating its most advanced product candidate, cemsidomide (CFT7455), an ora ...